The role of postmastectomy radiotherapy in clinically nodepositive, stage II-III breast cancer patients with pathological negative nodes after neoadjuvant chemotherapy

An analysis from the NCDB

Jieqiong Liu, Kai Mao, Shuai Jiang, Wen Jiang, Kai Chen, Y S Betty Kim, Qiang Liu, Lisa K. Jacobs

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose: The role of postmastectomy radiotherapy (PMRT) in clinically nodepositive, stage II-III breast cancer patients with pathological negative nodes (ypN0) after neoadjuvant chemotherapy (NAC) remains controversial. Methods: A total of 1560 clinically node-positive, stage II-III breast cancer patients treated with NAC and mastectomy who achieved ypN0 between 1998 and 2009 in the National Cancer Database were analyzed. The effects of PMRT on overall survival (OS) for the entire cohort and multiple subgroups were evaluated. Imputation and propensity score matching were used as sensitivity analyses to minimize biases. Results: Of the entire 1560 eligible patients, 903 (57.9%) received PMRT and 657 (42.1%) didn't. At a median follow-up of 56.0 months, no statistical difference was observed for OS between two groups by univariate and multivariate analyses (P = 0.120; HR 1.571, 95% CI 0.839-2.943). On subgroup analyses, PMRT significantly improved OS in patients with clinical stage IIIB/IIIC disease, T3/T4 tumor, or residual invasive breast cancer after NAC (P < 0.05). This improvement in OS remained significant after sensitivity analyses for the propensity score-matched patients. Conclusions: This study demonstrated that PMRT showed a heterogeneous effect in clinically node-positive, stage II-III breast cancer patients with ypN0 following NAC. PMRT improved OS for patients with clinical stage IIIB/IIIC disease, T3/T4 tumor, or residual invasive breast tumor after NAC. In the absence of definitive conclusions from prospective studies, including the ongoing NSABP B-51 trial, our findings may help identify specific groups of women with clinically node-positive, stage II-III breast cancers who could benefit from PMRT after NAC.

Original languageEnglish (US)
Pages (from-to)24848-24859
Number of pages12
JournalOncotarget
Volume7
Issue number17
DOIs
StatePublished - Apr 26 2016

Fingerprint

Radiotherapy
Breast Neoplasms
Drug Therapy
Survival
Propensity Score
Residual Neoplasm
Mastectomy
Multivariate Analysis
Databases
Prospective Studies
Neoplasms

Keywords

  • Breast cancer
  • Complete pathological nodal response
  • Neoadjuvant chemotherapy
  • Postmastectomy radiotherapy
  • Survival benefit

ASJC Scopus subject areas

  • Oncology

Cite this

The role of postmastectomy radiotherapy in clinically nodepositive, stage II-III breast cancer patients with pathological negative nodes after neoadjuvant chemotherapy : An analysis from the NCDB. / Liu, Jieqiong; Mao, Kai; Jiang, Shuai; Jiang, Wen; Chen, Kai; Kim, Y S Betty; Liu, Qiang; Jacobs, Lisa K.

In: Oncotarget, Vol. 7, No. 17, 26.04.2016, p. 24848-24859.

Research output: Contribution to journalArticle

@article{73a8066dbc2a4772a2d3543bd724478d,
title = "The role of postmastectomy radiotherapy in clinically nodepositive, stage II-III breast cancer patients with pathological negative nodes after neoadjuvant chemotherapy: An analysis from the NCDB",
abstract = "Purpose: The role of postmastectomy radiotherapy (PMRT) in clinically nodepositive, stage II-III breast cancer patients with pathological negative nodes (ypN0) after neoadjuvant chemotherapy (NAC) remains controversial. Methods: A total of 1560 clinically node-positive, stage II-III breast cancer patients treated with NAC and mastectomy who achieved ypN0 between 1998 and 2009 in the National Cancer Database were analyzed. The effects of PMRT on overall survival (OS) for the entire cohort and multiple subgroups were evaluated. Imputation and propensity score matching were used as sensitivity analyses to minimize biases. Results: Of the entire 1560 eligible patients, 903 (57.9{\%}) received PMRT and 657 (42.1{\%}) didn't. At a median follow-up of 56.0 months, no statistical difference was observed for OS between two groups by univariate and multivariate analyses (P = 0.120; HR 1.571, 95{\%} CI 0.839-2.943). On subgroup analyses, PMRT significantly improved OS in patients with clinical stage IIIB/IIIC disease, T3/T4 tumor, or residual invasive breast cancer after NAC (P < 0.05). This improvement in OS remained significant after sensitivity analyses for the propensity score-matched patients. Conclusions: This study demonstrated that PMRT showed a heterogeneous effect in clinically node-positive, stage II-III breast cancer patients with ypN0 following NAC. PMRT improved OS for patients with clinical stage IIIB/IIIC disease, T3/T4 tumor, or residual invasive breast tumor after NAC. In the absence of definitive conclusions from prospective studies, including the ongoing NSABP B-51 trial, our findings may help identify specific groups of women with clinically node-positive, stage II-III breast cancers who could benefit from PMRT after NAC.",
keywords = "Breast cancer, Complete pathological nodal response, Neoadjuvant chemotherapy, Postmastectomy radiotherapy, Survival benefit",
author = "Jieqiong Liu and Kai Mao and Shuai Jiang and Wen Jiang and Kai Chen and Kim, {Y S Betty} and Qiang Liu and Jacobs, {Lisa K.}",
year = "2016",
month = "4",
day = "26",
doi = "10.18632/oncotarget.6664",
language = "English (US)",
volume = "7",
pages = "24848--24859",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "17",

}

TY - JOUR

T1 - The role of postmastectomy radiotherapy in clinically nodepositive, stage II-III breast cancer patients with pathological negative nodes after neoadjuvant chemotherapy

T2 - An analysis from the NCDB

AU - Liu, Jieqiong

AU - Mao, Kai

AU - Jiang, Shuai

AU - Jiang, Wen

AU - Chen, Kai

AU - Kim, Y S Betty

AU - Liu, Qiang

AU - Jacobs, Lisa K.

PY - 2016/4/26

Y1 - 2016/4/26

N2 - Purpose: The role of postmastectomy radiotherapy (PMRT) in clinically nodepositive, stage II-III breast cancer patients with pathological negative nodes (ypN0) after neoadjuvant chemotherapy (NAC) remains controversial. Methods: A total of 1560 clinically node-positive, stage II-III breast cancer patients treated with NAC and mastectomy who achieved ypN0 between 1998 and 2009 in the National Cancer Database were analyzed. The effects of PMRT on overall survival (OS) for the entire cohort and multiple subgroups were evaluated. Imputation and propensity score matching were used as sensitivity analyses to minimize biases. Results: Of the entire 1560 eligible patients, 903 (57.9%) received PMRT and 657 (42.1%) didn't. At a median follow-up of 56.0 months, no statistical difference was observed for OS between two groups by univariate and multivariate analyses (P = 0.120; HR 1.571, 95% CI 0.839-2.943). On subgroup analyses, PMRT significantly improved OS in patients with clinical stage IIIB/IIIC disease, T3/T4 tumor, or residual invasive breast cancer after NAC (P < 0.05). This improvement in OS remained significant after sensitivity analyses for the propensity score-matched patients. Conclusions: This study demonstrated that PMRT showed a heterogeneous effect in clinically node-positive, stage II-III breast cancer patients with ypN0 following NAC. PMRT improved OS for patients with clinical stage IIIB/IIIC disease, T3/T4 tumor, or residual invasive breast tumor after NAC. In the absence of definitive conclusions from prospective studies, including the ongoing NSABP B-51 trial, our findings may help identify specific groups of women with clinically node-positive, stage II-III breast cancers who could benefit from PMRT after NAC.

AB - Purpose: The role of postmastectomy radiotherapy (PMRT) in clinically nodepositive, stage II-III breast cancer patients with pathological negative nodes (ypN0) after neoadjuvant chemotherapy (NAC) remains controversial. Methods: A total of 1560 clinically node-positive, stage II-III breast cancer patients treated with NAC and mastectomy who achieved ypN0 between 1998 and 2009 in the National Cancer Database were analyzed. The effects of PMRT on overall survival (OS) for the entire cohort and multiple subgroups were evaluated. Imputation and propensity score matching were used as sensitivity analyses to minimize biases. Results: Of the entire 1560 eligible patients, 903 (57.9%) received PMRT and 657 (42.1%) didn't. At a median follow-up of 56.0 months, no statistical difference was observed for OS between two groups by univariate and multivariate analyses (P = 0.120; HR 1.571, 95% CI 0.839-2.943). On subgroup analyses, PMRT significantly improved OS in patients with clinical stage IIIB/IIIC disease, T3/T4 tumor, or residual invasive breast cancer after NAC (P < 0.05). This improvement in OS remained significant after sensitivity analyses for the propensity score-matched patients. Conclusions: This study demonstrated that PMRT showed a heterogeneous effect in clinically node-positive, stage II-III breast cancer patients with ypN0 following NAC. PMRT improved OS for patients with clinical stage IIIB/IIIC disease, T3/T4 tumor, or residual invasive breast tumor after NAC. In the absence of definitive conclusions from prospective studies, including the ongoing NSABP B-51 trial, our findings may help identify specific groups of women with clinically node-positive, stage II-III breast cancers who could benefit from PMRT after NAC.

KW - Breast cancer

KW - Complete pathological nodal response

KW - Neoadjuvant chemotherapy

KW - Postmastectomy radiotherapy

KW - Survival benefit

UR - http://www.scopus.com/inward/record.url?scp=84966671397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84966671397&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.6664

DO - 10.18632/oncotarget.6664

M3 - Article

VL - 7

SP - 24848

EP - 24859

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 17

ER -